Hideomi Yamashita

Summary

Affiliation: University of Tokyo
Country: Japan

Publications

  1. request reprint
    Yamashita H, Nakagawa K, Tago M, Igaki H, Nakamura N, Shiraishi K, et al. The experience of concurrent chemoradiation for Japanese patients with superficial esophageal squamous cell carcinoma: a retrospective study. Am J Clin Oncol. 2005;28:555-9 pubmed
    ..Although this study was not randomized, the results showed that cCRT is a safe and effective method for treating patients with superficial esophageal cancer. ..
  2. request reprint
    Yamashita H, Nakagawa K, Tago M, Nakamura N, Shiraishi K, Eda M, et al. Taste dysfunction in patients receiving radiotherapy. Head Neck. 2006;28:508-16 pubmed
    ..The main cause of taste disorder resulting from RT was believed to be a disappearance of taste buds and not damage to the taste nerves. ..
  3. Yamashita H, Takenaka R, Sakumi A, Haga A, Otomo K, Nakagawa K. Analysis of motion of the rectum during preoperative intensity modulated radiation therapy for rectal cancer using cone-beam computed tomography. Radiat Oncol. 2015;10:2 pubmed publisher
    ..In this study, we estimated the motion of the rectum using planning CT and CBCT. Ten to fifteen mm is a sufficient margin for the rectum during SIB-IMRT for rectal cancer in the supine position. ..
  4. request reprint
    Yamashita H, Nakagawa K, Tago M, Nakamura N, Shiraishi K, Ohtomo K. Salvage radiotherapy for postoperative loco-regional recurrence of esophageal cancer. Dis Esophagus. 2005;18:215-20 pubmed
    ..Additionally, there is symptomatic relief in a substantial proportion of such patients, and long-term survival is possible in some patients. ..
  5. Yamashita H, Kobayashi Shibata S, Terahara A, Okuma K, Haga A, Wakui R, et al. Prescreening based on the presence of CT-scan abnormalities and biomarkers (KL-6 and SP-D) may reduce severe radiation pneumonitis after stereotactic radiotherapy. Radiat Oncol. 2010;5:32 pubmed publisher
    ..Therefore, pre-screening before SBRT for an IP shadow in CT and serum KL-6 & SP-D is recommended in the management and treatment of patients with primary or secondary lung tumors. ..